Skip to main content
. Author manuscript; available in PMC: 2023 Apr 1.
Published in final edited form as: Prostate Cancer Prostatic Dis. 2022 Jan 11;25(4):713–719. doi: 10.1038/s41391-021-00484-4

Table 2.

Cox regression comparing between high- and low-volume disease definitions for rPFS, tdCRPC, and OS.

Definitions HR (95%CI) p value
High volume
rPFS (vs Numeric >3)
 Numeric >5 0.95 (0.65–1.38) 0.78
 CHAARTED 0.91(0.62–1.33) 0.62
 STAMPEDE 0.92 (0.64–1.32) 0.64
tdCRPC (vs Numeric >3)
 Numeric >5 1.11 (0.79–1.54) 0.55
 CHAARTED 0.91 (0.65–1.27) 0.59
 STAMPEDE 0.98 (0.71–1.35) 0.89
OS (vs Numeric >3)
 Numeric >5 1.02 (0.59–1.75) 0.96
 CHAARTED 0.87 (0.51–1.51) 0.63
 STAMPEDE 0.95 (0.56–1.60) 0.84
Low Volume
rPFS (vs Numeric ≤3)
 Numeric ≤5 1.10 (0.78–1.54) 0.59
 CHAARTED 1.09 (0.77–1.53) 0.63
 STAMPEDE 1.13 (0.81–1.58) 0.48
tdCRPC (vs Numeric ≤3)
 Numeric ≤5 1.09 (0.77–1.53) 0.64
 CHAARTED 1.07 (0.75–1.51) 0.72
 STAMPEDE 1.21 (0.87–1.70) 0.26
OS (vs Numeric ≤3)
 Numeric ≤5 1.28 (0.66–2.48) 0.47
 CHAARTED 1.14 (0.57–2.29) 0.71
 STAMPEDE 1.38 (0.71–2.68) 0.34

rPFS radiographic progression free survival, tdCRPC time to castration resistance, OS Overall Survival